Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Event-driven oncology trade: recent positive AMTAGVI data (strong response and disease-control rates) and 50% ORR in a sarcoma pilot have driven a ~100% move off midâFebruary lows, with earnings also beating on revenue and margins. With multiple upcoming TIL program updates and manufacturing transition milestones, IOVA remains a high-volatility name where additional clinical or commercialization news could trigger further short-term upside swings.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Improvement ⢠Strong Liquidity ⢠Persistent Cash Burn IOVA shows improving margins and strong liquidity, but persistent losses, heavy cash burn, dilution, and an elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly gain ⢠Key $8 support ⢠Heavy resistance Support Level: $8.00â$8.10 (secondary: $7.00â$7.10) Resistance Level: $8.70â$9.00 IOVA gained 32% over the last month and remains bullish above $8.00â$8.10 support, but high volatility warrants caution near $8.70â$9.00 resistance.
Sentiment & News
Key News Insights: ⢠Amtagvi Sales ⢠Pipeline Catalysts ⢠Institutional Buying Iovance surged on strong Amtagvi sales, growth guidance, and pipeline catalysts, with institutional buying reinforcing positive momentum amid emerging competition.
AI Summary
IOVA has shifted from a binary pre-commercial bet to a commercial-scale execution story: Amtagvi's accelerating sales and 56% gross margin support upside, but investors should require evidence that gross profit can cover operating expenses and reduce cash burn before treating the rally as sustainable.
Description
Iovance Biotherapeutics is a clinical-stage biotechnology company that develops cell-based cancer immunotherapies using patients' own immune cells to target tumors. Its lead candidates, including lifileucel and LN-145, are being evaluated in multiple phase 2 trials for indications such as metastatic melanoma, cervical cancer and head and neck cancer. The company maintains collaborations and licensing arrangements with academic cancer centers and pharmaceutical partners, was founded in 2007, changed its name from Lion Biotechnologies in 2017, and is headquartered in San Carlos, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | IOVA | Iovance Biotherapeutics, Inc. | Event-driven oncology trade: recent positive AMTAGVI data (strong response and disease-control rates) and 50% ORR in a sarcoma pilot have driven a ~100% move off midâFebruary lows, with earnings also beating on revenue and margins. With multiple upcoming TIL program updates and manufacturing transition milestones, IOVA remains a high-volatility name where additional clinical or commercialization news could trigger further short-term upside swings. | Closed | -25.2% |
| Feb 25 | Mar 4 | IOVA | Iovance Biotherapeutics, Inc. | Nearâterm biotech momentum play: strong new clinical data (â50â52% ORR, 73% disease control in lifileucel/Amtagvi programs) and a large gapâup (~31% 21âday gain, ~39% above 21âday SMA) ahead of the 2026â02â24 Q4/webcast create a highâvolatility breakout with active newsflow and technical followâthrough potential over the next few days. | Closed | +11.2% |